Concord Wealth Partners Ardelyx, Inc. Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Ardelyx, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 8 shares of ARDX stock, worth $33. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8Holding current value
$33% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARDX
# of Institutions
233Shares Held
166MCall Options Held
490KPut Options Held
2.35M-
Janus Henderson Group PLC London, X025MShares$106 Million0.07% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$74.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15MShares$63.6 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C311.2MShares$47.3 Million0.07% of portfolio
-
State Street Corp Boston, MA10.2MShares$43.1 Million0.0% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $656M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...